Archive
Here you can find the archive of all Press Releases prior to 2018
Filter by date:
Showing 677 press releases before 2019
-
AstraZeneca to present comprehensive data from its diabetes portfolio and pre-clinical research at EASD 2015
-
AstraZeneca purchases US biologics manufacturing facility to support growing pipeline
-
AstraZeneca to invest £11.5 million in new clinical oncology bioinformatics collaboration with The University of Manchester
-
AstraZeneca to update on leading lung cancer portfolio at WCLC 2015
-
US FDA approves expanded indication for BRILINTA to include long-term use in patients with a history of heart attack
-
AstraZeneca enters license agreement with Daiichi Sankyo for development and commercialisation of FluMist in Japan
-
Positive Phase III results demonstrate efficacy of antibiotic medicine CAZ-AVI in complicated Urinary Tract Infections
-
AstraZeneca and Valeant Pharmaceuticals to partner on brodalumab
-
PEGASUS-TIMI 54 sub-analysis shows importance of continuing treatment with BRILINTA beyond one year following a heart attack
-
AstraZeneca to present further research into long-term prevention of cardiovascular events for patients with a history of heart attack at ESC Congress 2015
Latest articles and press releases
All of our latest press releases and articles are available to explore
Contact us
Email the Global Media Relations team at:
Gonzalo Viña
Head of Global Media Relations
+44 (0)1223 344 800
Kim Blomley
Director Global Media Relations (Oncology)
+44 (0)1223 344 800
Matthew Kent
Director Global Media Relations (BioPharmaceuticals)
+44 (0)1223 344 800
Angela Fiorin
Director Global Media Relations (BioPharmaceuticals)
+44 (0)1223 344 800
Fiona Cookson
Director Global Media Relations (Covid-19)
+44 (0)1223 344 800
Christina Malmberg Hägerstrand
Media Relations Director, Sweden and Nordic-Baltic
+46 855 253 106
